ArticleCurrent microbiology2025
Protection of Mice Vaccinated with a New B Cell and T Cell Epitopes Cocktail from Staphylococcus aureus Challenge in Skin Infection Model.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peptide vaccines: an innovative therapeutic approach against antibiotic-resistant bacterial infections.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Developing an effective vaccine against Staphylococcus aureus (S. aureus) is a key global health concern, especially with the increased reports of multidrug-resistant (MDR) S. aureus strains. Previous attempts for S. aureus vaccine development were unsuccessful. In this study, Manganese transport protein C (MABC) B cell epitopes, Nickel ABC transporter (NABC) B cell & T cell epitopes, and Phosphatidylinositol phosphodiesterase (PIc) B cell & T cell epitopes were used as a vaccine in mice skin infection model. Mice immunized with peptide mixture and MABC peptide group showed the best skin lesion healing results. The protection level was correlated with the highest IgG level, highest levels of interferon-gamma (INF γ), and lowest levels of interleukin-2 (IL-2). The peptide mixture group also showed the highest count of CD4/ CD8 cells. Results demonstrated that the inclusion of B cell and T cell epitopes of multiple genes improved both the humoral and cellular immunity and resulted in the best outcome in the skin infection mice model. A more expanded in-vivo study in different mice models is recommended for testing MABC, NABC, and PIc B cells and T cells peptides cocktail as promising S. aureus vaccine.
Indexed as
Identifiers
39922982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.